AZD4063

Unknown / undisclosed

Automated registry profile: compiled from public clinical-trial and regulatory records; not yet individually analyst-verified.

Earlyevidence

Evidence outlook

Early-stage evidence only

Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 1 (1)
Dilated Cardiomyopathy
NCT07241104 · AstraZeneca
2025-12-01 – 2027-11-22 · Dilated Cardiomyopathy
What this study did

Competitive landscape

This drug's own stage for Dilated Cardiomyopathy: Phase 1. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
AZD4063: this drugPhase 1UndisclosedPhospholamban (PLN)not yet gradedNo reviewed efficacy summary in this indication
ALXN2350Phase 1/2Gene therapy / editing—not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow AZD4063 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
November 2027 (1)
Phase 1Dilated CardiomyopathyRecruiting
Est. primary completion 2027-11-22 · NCT07241104 · CT.gov ↗
What to watch

See the full readout calendar ↗